Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study].

被引：5

作者：

Kim, Jisun

Han, Wonshik

Kim, Eun-Kyu

Jung, Yongsik

Kim, Hyun-Ah

Chae, Soo Min

Lee, Eun Sook

Ahn, Sei-Hyun

Kim, Tae Hyun

Jeong, Joon

Choi, Su Yun

Nam, Seok Jin

Paik, Nam-Sun

Kim, Lee Su

Gong, Gyungyub

Yu, Jong Han

Jung, So-Youn

Kim, Hee Jeong

Ahn, Sung Gwe

Kim, Min Kyoon

机构：

[1] Asan Med Ctr, Dept Surg, Seoul, South Korea

[2] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea

[3] Seoul Natl Univ, Bundang Hosp, Dept Surg, Seongnam, South Korea

[4] Ajou Univ Hosp, Suwon, South Korea

[5] Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Seoul, South Korea

[6] Seoul Natl Univ, Bundang Hosp, Dept Surg, Seoul, South Korea

[7] Natl Canc Ctr, Ctr Breast Canc, Goyang Si, South Korea

[8] Univ Ulsan, Coll Med, Dept Surg, Seoul, South Korea

[9] ASAN Med Ctr, Seoul, South Korea

[10] Inje Univ, Busan Paik Hosp, Dept Surg, Busan, South Korea

[11] Yonsei Univ Hlth Syst, Seoul, South Korea

[12] Hallym Univ, Coll Med, Kangdong Sacred Heart Hosp, Div Breast & Endocrine Surg, Seoul, South Korea

[13] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[14] Ewha Womans Univ, Sch Med, Dept Surg, Seoul, South Korea

[15] Hallym Univ, Coll Med, Sacred Heart Hosp, Div Breast & Endocrine Surg, Anyang, South Korea

[16] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[17] Natl Canc Ctr, Ctr Breast Canc, Goyang, South Korea

[18] Gangnam Severance Hosp, Seoul, South Korea

[19] Chung Ang Univ, Coll Med, Dept Surg, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.576

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

576

引用

页数：2

共 50 条

[1] Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
Jisun Kim
Woosung Lim
Eun-Kyu Kim
Min-Kyoon Kim
Nam-Sun Paik
Sang-Seol Jeong
Jung-han Yoon
Chan Heun Park
Sei Hyun Ahn
Lee Su Kim
Sehwan Han
Seok Jin Nam
Han-Sung Kang
Seung Il Kim
Young Bum Yoo
Joon Jeong
Tae Hyun Kim
Taewoo Kang
Sung-Won Kim
Yongsik Jung
Jeong Eon Lee
Ku Sang Kim
Jong-Han Yu
Byung Joo Chae
So-Youn Jung
Eunyoung Kang
Su Yun Choi
Hyeong-Gon Moon
Dong-Young Noh
Wonshik Han
[J]. BMC Cancer, 14
[2] Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
Kim, Jisun
Lim, Woosung
Kim, Eun-Kyu
Kim, Min-Kyoon
Paik, Nam-Sun
Jeong, Sang-Seol
Yoon, Jung-han
Park, Chan Heun
Ahn, Sei Hyun
Kim, Lee Su
Han, Sehwan
Nam, Seok Jin
Kang, Han-Sung
Kim, Seung Il
Yoo, Young Bum
Jeong, Joon
Kim, Tae Hyun
Kang, Taewoo
Kim, Sung-Won
Jung, Yongsik
Lee, Jeong Eon
Kim, Ku Sang
Yu, Jong-Han
Chae, Byung Joo
Jung, So-Youn
Kang, Eunyoung
Choi, Su Yun
Moon, Hyeong-Gon
Noh, Dong-Young
Han, Wonshik
[J]. BMC CANCER, 2014, 14
[3] Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
Baselga, Jose
Semiglazov, Vladimir
van Dam, Peter
Manikhas, Alexey
Bellet, Meritxell
Mayordomo, Jose
Campone, Mario
Kubista, Ernst
Greil, Richard
Bianchi, Giulia
Steinseifer, Jutta
Molloy, Betty
Tokaji, Erika
Gardner, Humphrey
Phillips, Penny
Stumm, Michael
Lane, Heidi A.
Dixon, J. Michael
Jonat, Walter
Rugo, Hope S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2630 - 2637
[4] LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer
Saura, Cristina
de Azambuja, Evandro
Dubsky, Peter
Oliveira, Mafalda
Saini, Kamal S.
Fes, Christian
Lin, Ray S.
Wilson, Timothy R.
Fredickson, Jill
Parmar, Hema
Hsu, Jerry Y.
Piccard, Martine
Gnant, Michael
Baselga, Jose
[J]. CANCER RESEARCH, 2015, 75
[5] Letrozole plus ribociclib versus letrozole plus placebo as neoadjuvant therapy for ER plus breast cancer (FELINE trial).
Khan, Qamar J.
O'Dea, Anne
Bardia, Aditya
Kalinsky, Kevin
Wisinski, Kari Braun
O'Regan, Ruth
Yuan, Yuan
Ma, Cynthia X.
Jahanzeb, Mohammad
Trivedi, Meghna S.
Spring, Laura
Makhoul, Issam
Wagner, Jamie L.
Winblad, Onalisa
Amin, Amanda Leigh
Blau, Sibel
Crane, Gregory James
Elia, Manana
Hard, Mia
Sharma, Priyanka
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer
Oliveira, M.
de Azambuja, E.
Saura, C.
Dubsky, P.
Zardavas, D.
Fesl, C.
Bardia, A.
Soberino, J.
Gil, E. Ciruelos
Ng, V.
Fredrickson, J.
Stout, T. J.
Singel, S. M.
Hsu, J. Y.
Piccart, M.
Gnant, M.
Baselga, J.
[J]. CANCER RESEARCH, 2016, 76
[7] LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.
De Azambuja, Evandro
Saura, Cristina
Oliveira, Mafalda
Dubsky, Peter Christian
Zardavas, Dimitrios
Fesl, Christian
Bardia, Aditya
Lin, Ray
Fredrickson, Jill O.
Parmar, Hema
Singel, Stina Mui
Hsu, Jerry Y.
Piccart-Gebhart, Martine J.
Gnant, Michael
Baselga, Jose
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.
Saura, Cristina
De Azambuja, Evandro
Oliveira, Mafalda
Dubsky, Peter Christian
Zardavas, Dimitrios
Fesl, Christian
Bardia, Aditya
Soberino, Jesus
Fornier, Monica N.
Boer, Katalin
Ng, Vivian
Fredrickson, Jill O.
Stout, Thomas
Singel, Stina
Hsu, Jerry Y.
Piccart-Gebhart, Martine J.
Baselga, Jose
Gnant, Michael
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[9] Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer
de Azambuja, Evandro
Saura, Cristina
Nuciforo, Paolo
Frantal, Sophie
Oliveira, Mafalda
Zardavas, Dimitrios
Jallitsch-Halper, Anita
de la Pena, Lorena
Dubsky, Peter
Lombard, Janine M.
Vuylsteke, Peter
Altamirano, Carlos Castaneda
Sanchez, Cesar
Ballestrero, Alberto
Colleoni, Marco
Borges, Giuliano Santos
Ciruelos, Eva
Bardia, Aditya
Fornier, Monica
Boer, Katalin
Wilson, Tim R.
Stout, Thomas J.
Hsu, Jerry Y.
Shi, Yi
Piccart, Martine
Baselga, Jose
Gnant, Michael
[J]. CANCER RESEARCH, 2018, 78 (04)
[10] Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER plus breast cancer
Baselga, J.
van Dam, P. A.
Greil, R.
Gardner, H.
Bandaru, R.
Molloy, B.
Steinseifer, J.
Phillips, P.
Dixon, J. M.
Rugo, H. S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →